Topics

4/19/18

Research led by Andrew H. Talal, MD, professor of medicine in the Division of Gastroenterology, Hepatology and Nutrition, involving hepatic pharmokinetics and pharmacodynamics was the first-place winner in the Buffalo Translational Consortium (BTC) 2017 Clinical Research Achievement Awards.

3/21/18

Medical students and residents at the Jacobs School of Medicine and Biomedical Sciences stand to benefit from a new partnership between UBMD Internal Medicine and Evergreen Health to care for patients with HIV and hepatitis C.

5/17/17

The Department of Medicine’s Division of General Internal Medicine had a strong showing at the 2017 Society of General Internal Medicine (SGIM) annual meeting with 11 research posters and one oral presentation.

5/3/17

UB researchers are developing innovative ways to better diagnose and treat hepatitis C virus (HCV) in people with substance abuse disorders.

6/9/16

Andrew H. Talal, MD, professor of medicine in the Division of Gastroenterology, Hepatology and Nutrition, has received a $7 million grant to develop an effective way to treat drug users with the hepatitis C virus (HCV).

10/20/14

Federal approval of new drugs to treat the hepatitis C virus (HCV) represents “a dramatic, positive development for patients,” says University at Buffalo liver disease expert Andrew H. Talal, MD.

8/11/14

University at Buffalo experts in the Division of Gastroenterology, Hepatology and Nutrition are contributing co-authors of HCV Next, the first multidisciplinary publication focused exclusively on the hepatitis C virus.

7/11/14

Research co-authored by Andrew H. Talal, MD, shows that injection drug users who are enrolled in a treatment program want to be educated about hepatitis C virus (HCV) and are willing to be treated.

6/24/14

A study led by Andrew H. Talal, MD, is the first to trace in real time how the drug telaprevir inhibits viral replication in the liver and clears hepatitis C virus (HCV) from the cells and plasma of infected patients.